uniQure’s AMT-130 Gene Therapy Shows Promising Results in Huntington’s Disease Trials, Justifying Buy Rating and $70 Price Target
Patrick Trucchio has reiterated a Buy rating for uniQure, citing promising results from AMT-130's Phase 1/2 trials for Huntington’s disease, which showed significant slowing of disease progression and reduced neurodegeneration biomarkers. The successful primary endpoint and potential for a Biologics License Application in early 2026 enhance the positive outlook. With robust safety data over 36 months, Trucchio sets a $70 price target for uniQure's stock, supported by his strong track record in the Healthcare sector.
Patrick Trucchio has given his Buy rating due to a combination of factors including the promising results from uniQure’s pivotal Phase 1/2 clinical trials for AMT-130, a gene therapy candidate for Huntington’s disease. The trials demonstrated a significant slowing in disease progression and a reduction in neurodegeneration biomarkers, which positions AMT-130 as a leading candidate for addressing this serious condition with no current disease-modifying treatments.
Furthermore, the successful meeting of the trial’s primary endpoint and the potential for a Biologics License Application filing in the first quarter of 2026, along with a possible accelerated approval, contribute to the positive outlook. The robust data, including safety and tolerability over 36 months, support the confidence in AMT-130’s potential, justifying the reiterated Buy rating and the $70 price target for uniQure’s stock.
According to TipRanks, Trucchio is a 5-star analyst with an average return of 15.2% and a 46.19% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as GH Research, Arrowhead Pharmaceuticals, and Oncolytics Biotech.
